Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04599140 |
TitleSX-682和Nivolumab治疗RAS突变、MSS不可切除或转移性结直肠癌的STOPTRAFFIC-1试验 | 阶段
第 1 阶段
|
Date Added 2020-10-22 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
CXCR1/2 Inhibitor SX-682, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT04724239 |
TitleA Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | 阶段
第二阶段
|
Date Added 2021-01-26 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
chidamide, IBI305, Sintilimab |
标签
MSS/ MMRp
|
| NCT ID NCT06566755 |
TitleCadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer | 阶段
第三阶段
|
Date Added 2024-08-22 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06589440 |
TitlePhase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | 阶段
第二阶段
|
Date Added 2024-09-19 |
地点
New Jersey, United States
Texas, United States Washington, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Balstilimab, Botensilimab |
标签
MSS/ MMRp
|
| NCT ID NCT06493760 |
TitleA Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | 阶段
第二阶段
|
Date Added 2024-07-10 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06513221 |
TitleA Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab | 阶段 |
Date Added 2024-07-22 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status |
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06788171 |
TitlePULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM | 阶段
第二阶段
|
Date Added 2025-03-25 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06794086 |
TitleSBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases | 阶段
第三阶段
|
Date Added 2025-01-27 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06792695 |
TitleA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | 阶段
第二阶段
|
Date Added 2025-03-25 |
地点
Arizona, United States
California, United States District of Columbia, United States Illinois, United States Maryland, United States Massachusetts, United States Minnesota, United States New York, United States Ohio, United States Texas, United States 澳大利亚 加拿大 中国 法国 德国 意大利 大韩民国 西班牙 台湾 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06801665 |
TitleFMT+ QL1706+bevacizumab+ XELOX As First-line Treatment for Advanced MSS-type Colon Cancer with Liver Metastasis | 阶段
第二阶段
|
Date Added 2025-01-30 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
